Abstract: The present invention relates to a VHH which binds to a growth factor or is an antagonist for a growth factor, or binds to an implant.

Abstract: The present disclosure relates to in situ tissue engineering, more specifically in situ vascular tissue engineering with the aim of providing a tissue structure which can be used e.g. as a substitute blood vessel or as a blood vessel functioning as cannulation site in hemodialysis. In particular, the disclosure involves tissue structure formation around a subcutaneously implanted synthetic rod. In addition, the disclosure involves a method for producing said synthetic rod.

Abstract: The present disclosure relates to in situ tissue engineering, more specifically in situ vascular tissue engineering with the aim of providing a tissue structure which can be used e.g. as a substitute blood vessel or as a blood vessel functioning as cannulation site in hemodialysis. In particular, the disclosure involves tissue structure formation around a subcutaneously implanted synthetic rod. In addition, the disclosure involves a method for producing said synthetic rod.

Abstract: The present disclosure relates to in situ tissue engineering, more specifically in situ vascular tissue engineering with the aim of providing a tissue structure which can be used e.g. as a substitute blood vessel or as a blood vessel functioning as cannulation site in hemodialysis. In particular, the disclosure involves tissue structure formation around a subcutaneously implanted synthetic rod. In addition, the disclosure involves a method for producing said synthetic rod.

Abstract: A method for making an at least double layered cell aggregate and/or an artificial blastocyst, and/or a further-developed blastoid termed blastoid, by forming a double layered cell aggregate from at least one trophoblast cell and at least one pluripotent and/or totipotent cell, and culturing the aggregate to obtain an artificial blastocyst having a trophectoderm-like tissue that surrounds a blastocoel and an inner cell mass-like tissue. The cell aggregate can be formed from toti- or pluripotent stem cell types, or induced pluripotent stem cell types, in combination with trophoblast stem cells. Formation of a blastoid can be achieved by culturing the cell aggregate in a medium preferably comprising one or more of a Rho/ROCK inhibitor, a Wnt pathway modulator, a PKA pathway modulator, a PKC pathway modulator, a MAPK pathway modulator, a STAT pathway modulator, an Akt pathway modulator, a Tgf pathway modulator and a Hippo pathway modulator.

Abstract: The present disclosure relates to in situ tissue engineering, more specifically in situ vascular tissue engineering with the aim of providing a tissue structure which can be used e.g. as a substitute blood vessel or as a blood vessel functioning as cannulation site in hemodialysis. In particular, the disclosure involves tissue structure formation around a subcutaneously implanted synthetic rod. In addition, the disclosure involves a method for producing said synthetic rod.

Abstract: The present invention relates to a VHH which binds to a growth factor or is an antagonist for a growth factor, or binds to an implant.

Abstract: The disclosure relates to a new approach to constructing cellular aggregates in vitro and their use in methods for producing 3D-tissue constructs in a modular way. In particular, the disclosure is directed to a method for in vitro producing a tissue construct comprising: a) combining living cells to form supracellular aggregates using spatial confinement; b) combining two or more of the supracellular aggregates in a mold or on a biomaterial; c) applying conditions that induce self-assembly within the combined supracellular aggregates to obtain the tissue construct; and d) applying conditions that induce tissue morphogenesis in the tissue construct.

Abstract: The invention is directed to a treatment of diabetes, a scaffold and a method of preparing a scaffold. In a first aspect, this object is met by providing a scaffold comprising beta cell aggregates, wherein the aggregates are distributed over the scaffold in a predetermined pattern.

Abstract: The present invention relates to a VHH which binds to a growth factor or is an antagonist for a growth factor, or binds to an implant.

Abstract: The invention relates to a new approach to constructing cellular aggregates in vitro and their use in methods for producing 3D-tissue constructs in a modular way. In particular, the invention is directed to a method for in vitro producing a tissue construct comprising: a) combining living cells to form supracellular aggregates using spatial confinement; b) combining two or more of the supracellular aggregates in a mold or on a biomaterial; c) applying conditions that induce self-assembly within the combined supracellular aggregates to obtain the tissue construct; and d) applying conditions that induce tissue morphogenesis in the tissue construct.

Abstract: The invention relates to a method for making an at least double layered cell aggregate and/or an artificial blastocyst, and/or a further-developed blastoid termed blastoid, by forming a double layered cell aggregate from at least one trophoblast cell and at least one pluripotent and/or totipotent cell, and culturing said aggregate to obtain an artificial blastocyst. This artificial blastocyst has a trophectoderm-like tissue that surrounds a blastocoel and an inner cell mass-like tissue. The cell aggregate can be formed from toti- or pluripotent stem cell types, or induced pluripotent stem cell types, in combination with trophoblast stem cells. Formation of a blastoid can be achieved by culturing the cell aggregate in a medium preferably comprising one or more of a Rho/ROCK inhibitor, a Wnt pathway modulator, a PKA pathway modulator, a PKC pathway modulator, a MAPK pathway modulator, a STAT pathway modulator, an Akt pathway modulator, a Tgf pathway modulator and a Hippo pathway modulator.

Abstract: The invention relates to a multiwell system, characterized that said multiwell system having at least 3 wells, wherein said wells have a volume between 0.125 and 4.0 mm3.

Abstract: The invention relates to a multiwell system, characterized that said multiwell system having at least 3 wells, wherein said wells have a volume between 0.125 and 4.0 mm3.

Abstract: The present invention relates to a VHH which binds to a growth factor or is an antagonist for a growth factor, or binds to an implant.

Abstract: The invention is directed to a treatment of diabetes, a scaffold and a method of preparing a scaffold. In a first aspect, this object is met by providing a scaffold comprising beta cell aggregates, wherein the aggregates are distributed over the scaffold in a predetermined pattern.

Abstract: The invention is directed to a high throughput screening method for analyzing and interaction between a surface of a material and an environment. The screening method of the invention comprises: providing a micro-array comprising said material and having a multitude of units at least part of which have different topography; contacting at least part of said multitude of units with said environment; and screening said micro-array for an interaction between one or more of said units and said environment.

Abstract: The invention relates to a method of determining in vitro the capacity of a cell population to induce bone formation in vivo comprising the steps of: a) providing a sample of a cell population; b) dividing said sample into a first and a second part containing an equal number of cells; c) culturing the first part in the presence of an osteogenic stimulation factor; d) culturing the second part in the absence of an osteogenic stimulation factor; e) determining degrees of expression of a bone-specific protein; and f) comparing the degrees of expression of the bone-specific protein of the first part and the second part thereby providing a measure for the capacity of the bone cell population to induce bone formation in vivo.

Abstract: A biodegradable, biocompatible porous matrix as a scaffold for tissue engineering cartilage is formed of a copolymer of a polyalkylene glycol and an aromatic polyester such as a polyethylene glycol/polybutylene terephtalate copolymer. A ceramic coating such as a calcium phosphate coating may be provided on the scaffold by soaking the scaffold in a solution containing calcium and phosphate ions. A composite scaffold which may be used as an implant is preferably a two-layer system may be formed having an outer surface of a layer of the porous matrix formed of the copolymer, and an outer surface of a layer of a ceramic material. The composite scaffold may be prepared by casting the copolymer on top of the ceramic material in a mould. Cells are preferably seeded on the scaffold prior to implanting, and the scaffold may contain bioactive agents that are released on degradation of the scaffold in vivo.

Abstract: The invention relates to a process for loading a polymer with one or more bioactive agents, using a wet spinning technique. The invention further relates to a polymer loaded with one or more bioactive agents, obtainable by said process and to the use thereof as a carrier for controlled drug release or as scaffold for tissue engineering.